ATE485283T1 - Inhibitoren der 11-beta-hydroxy-steroid- dehydrogenase des typs 1 - Google Patents

Inhibitoren der 11-beta-hydroxy-steroid- dehydrogenase des typs 1

Info

Publication number
ATE485283T1
ATE485283T1 AT01934782T AT01934782T ATE485283T1 AT E485283 T1 ATE485283 T1 AT E485283T1 AT 01934782 T AT01934782 T AT 01934782T AT 01934782 T AT01934782 T AT 01934782T AT E485283 T1 ATE485283 T1 AT E485283T1
Authority
AT
Austria
Prior art keywords
beta
hydroxy
type
dehydrogenase inhibitors
steroid dehydrogenase
Prior art date
Application number
AT01934782T
Other languages
English (en)
Inventor
Guido Kurz
Marianne Nilsson
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Application granted granted Critical
Publication of ATE485283T1 publication Critical patent/ATE485283T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01934782T 2000-05-22 2001-05-22 Inhibitoren der 11-beta-hydroxy-steroid- dehydrogenase des typs 1 ATE485283T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0001899A SE0001899D0 (sv) 2000-05-22 2000-05-22 New compounds
PCT/SE2001/001158 WO2001090092A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Publications (1)

Publication Number Publication Date
ATE485283T1 true ATE485283T1 (de) 2010-11-15

Family

ID=20279781

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01937063T ATE443055T1 (de) 2000-05-22 2001-05-22 Inhibitoren der 11-beta-hydroxy-steroid- dehydrogenase des typs 1
AT01934782T ATE485283T1 (de) 2000-05-22 2001-05-22 Inhibitoren der 11-beta-hydroxy-steroid- dehydrogenase des typs 1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01937063T ATE443055T1 (de) 2000-05-22 2001-05-22 Inhibitoren der 11-beta-hydroxy-steroid- dehydrogenase des typs 1

Country Status (23)

Country Link
US (7) US7618961B2 (de)
EP (4) EP1283832B1 (de)
JP (4) JP2003534336A (de)
KR (4) KR20030016269A (de)
CN (4) CN1437588A (de)
AR (1) AR033534A1 (de)
AT (2) ATE443055T1 (de)
AU (6) AU6093201A (de)
BR (1) BR0111099A (de)
CA (4) CA2408783A1 (de)
DE (3) DE60139931D1 (de)
EA (1) EA005274B1 (de)
ES (1) ES2333846T3 (de)
HU (1) HUP0302435A3 (de)
IL (4) IL152790A0 (de)
MX (1) MXPA02011632A (de)
NO (4) NO323831B1 (de)
NZ (4) NZ522507A (de)
PE (1) PE20020100A1 (de)
PL (1) PL360137A1 (de)
SE (1) SE0001899D0 (de)
WO (5) WO2001090094A1 (de)
ZA (4) ZA200209364B (de)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001276378A1 (en) * 2000-07-05 2002-01-14 Bayer Aktiengesellschaft Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
AU2007205749B2 (en) * 2001-11-22 2009-04-23 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
RS44204A (sr) * 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
WO2003044000A1 (en) * 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2002353718B2 (en) 2001-11-22 2007-05-10 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20030130279A1 (en) * 2001-11-22 2003-07-10 Guido Kurz Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
RS44304A (sr) * 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
JP2005529846A (ja) 2002-01-16 2005-10-06 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ１アデノシン受容体の２−アミノチアゾールアロステリックエンハンサ
WO2003065983A2 (en) * 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
US7338969B2 (en) * 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
EP2141143A3 (de) * 2002-03-29 2010-05-05 Schering Corporation Stereoselektive Alkylierung von Chirale 2-methyl-4-geschützte Piperazinen
SE0201194D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab New compounds
US20030198965A1 (en) 2002-04-19 2003-10-23 Isis Pharmaceuticals Inc. Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
AR040241A1 (es) * 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004027047A2 (en) * 2002-09-18 2004-04-01 Hanauske-Abel Hartmut M INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE AND USES THEREFOR
CA2501611A1 (en) * 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
GB0224830D0 (en) 2002-10-24 2002-12-04 Sterix Ltd Compound
EP1556040A1 (de) * 2002-10-24 2005-07-27 Sterix Limited Inhibitoren der 11-beta-hydroxy-steroid-dehydrogenase des typs 1 und des typ 2
JP2006514102A (ja) * 2002-11-07 2006-04-27 アストラゼネカ アクチボラグ ２−オキソ−エタンスルホンアミド誘導体
GB0226602D0 (en) * 2002-11-14 2002-12-24 Novartis Ag Organic compounds
AR041952A1 (es) * 2002-11-14 2005-06-01 Novartis Ag N-sulfonilaminotiazol
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
FR2849599B1 (fr) * 2003-01-07 2006-12-29 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
ATE467616T1 (de) * 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
DE602004025220D1 (de) 2003-04-11 2010-03-11 High Point Pharmaceuticals Llc Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen
EP1785424A3 (de) * 2003-04-11 2009-12-23 High Point Pharmaceuticals, LLC Kondensierte 1,2,4-Triazole und deren pharmazeutische Verwendungen
WO2004103980A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
US7173030B2 (en) 2003-05-21 2007-02-06 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US8026264B2 (en) 2003-05-29 2011-09-27 Merck Sharp And Dohme Corp. Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1
WO2004113310A1 (en) * 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
SE0301883D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use II
SE0301885D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use IV
SE0301882D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use I
SE0301884D0 (sv) * 2003-06-25 2003-06-25 Biovitrum Ab New use III
AU2004274309B2 (en) 2003-09-22 2010-04-08 Msd K.K. Novel piperidine derivative
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
GB0325745D0 (en) * 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
AP2006003633A0 (en) * 2003-12-19 2006-06-30 Pfizer Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-BETA-hydroxysteroid dehydrogenase type 1 (11-BETA-HSD-1) for the treatment of diabetes and obesity
JP2007515490A (ja) 2003-12-22 2007-06-14 アムジェン インコーポレーティッド アリールスルホンアミド化合物およびそれに関連する使用法
US7875642B2 (en) 2004-01-26 2011-01-25 Merck Sharp & Dohme Corp. Crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP2007261945A (ja) * 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd チアゾール誘導体
US7402704B2 (en) 2004-04-14 2008-07-22 Amgen Inc. Arylsulfones and uses related thereto
GB0408771D0 (en) * 2004-04-20 2004-05-26 Sterix Ltd Compound
JP2007533749A (ja) * 2004-04-20 2007-11-22 アムゲン インコーポレイティッド アリールスルホンアミドおよびそれに関連する使用方法
NZ551077A (en) 2004-05-07 2009-05-31 Janssen Pharmaceutica Nv Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
CN1964956B (zh) 2004-05-24 2013-03-27 安美基公司 11-β-羟基类固醇脱氢酶1型的抑制剂
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
DK1763517T3 (da) * 2004-06-28 2011-06-06 Hoffmann La Roche Pyrimidinderivater som 11beta-HSD1-inhibitorer
CA2575339A1 (en) * 2004-08-05 2006-02-09 F. Hoffmann-La Roche Ag Substituted n-acyl-2-aminothiazoles
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
BRPI0515121A (pt) 2004-08-30 2008-07-08 Janssen Pharmaceutica Nv derivados da n-2 adamantil-2-fenóxi acetamida como inibidores da 11-beta hidroxiesteróide desidrogenase
MY141198A (en) 2004-08-30 2010-03-31 Janssen Pharmaceutica Nv Tricyclic adamantylamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006034804A1 (en) 2004-09-29 2006-04-06 F.Hoffmann-La Roche Ag Indozolone derivatives as 11b-hsd1 inhibitors
EP1799647A1 (de) * 2004-10-04 2007-06-27 F.Hoffmann-La Roche Ag Alkylpyridine als 11-beta-inhibitoren gegen diabetes
KR101325519B1 (ko) * 2004-10-14 2013-11-08 애보트 게엠베하 운트 콤파니 카게 도파민 ｄ3 수용체의 조절에 반응하는 장애를 치료하기에적합한 아릴설포닐메틸 또는 아릴설폰아미드 치환된 방향족화합물
WO2006047302A1 (en) 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
EP1666467A1 (de) * 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitoren
EP1659113A1 (de) * 2004-11-08 2006-05-24 Evotec AG Hemmstoffe von 11beta-hydroxy steroid dehydrogenase Typ 1 (11beta-HSD1)
WO2006051662A1 (ja) * 2004-11-09 2006-05-18 Taisho Pharmaceutical Co., Ltd. チアゾール誘導体
WO2006059507A1 (ja) * 2004-11-30 2006-06-08 Sankyo Company, Limited 11β-HSD1アンチセンス化合物
JP2008524244A (ja) * 2004-12-17 2008-07-10 タケダ サン ディエゴ インコーポレイテッド 水酸化ステロイド脱水素酵素阻害剤
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
EP1866298A2 (de) 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroiddehydrogenase-hemmer
DK1928840T3 (da) 2005-04-05 2011-09-12 Hoffmann La Roche 1H-pyrazol-4-carboxamider, deres fremstilling og deres anvendelse som 11-beta-hydroxysteroid-dehydrogenaseinhibitorer
CA2609388C (en) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
AU2006257646A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-YL)-sulfonamide derivatives
WO2006134481A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
EP1921065B1 (de) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridonderivat
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
JP2007099659A (ja) * 2005-10-03 2007-04-19 Toray Fine Chemicals Co Ltd ピペラジンカルボン酸エステルの製造法
RU2008118350A (ru) * 2005-10-12 2009-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бифенильные производные в качестве модуляторов потенциалзависимых ионных каналов
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
US8158791B2 (en) 2005-11-10 2012-04-17 Msd K.K. Aza-substituted spiro derivatives
US20070110802A1 (en) * 2005-11-15 2007-05-17 Janan Jona Wet granulation process
CA2630718A1 (en) 2005-11-22 2007-05-31 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NZ593074A (en) 2005-12-21 2012-04-27 Vertex Pharma sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
BRPI0710479A2 (pt) 2006-01-18 2012-08-14 Hoffmann La Roche composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica.
EA016959B1 (ru) * 2006-04-24 2012-08-30 Эли Лилли Энд Компани Замещенные пирролидиноны в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы 1 типа
EP2049475B1 (de) * 2006-04-24 2012-02-01 Eli Lilly & Company Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
AU2007301126A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101668524B (zh) * 2007-02-12 2012-10-24 阿斯利康(瑞典)有限公司 作为11-β-HSD1抑制剂的吡唑衍生物
JP2010519239A (ja) 2007-02-23 2010-06-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのｎ−アドマンチルベンザミド
EP2125704A1 (de) 2007-02-23 2009-12-02 High Point Pharmaceuticals, LLC N-adamantylbenzamide als inhibitoren von 11-beta-hydroxysteroiddehydrogenase
ZA200904916B (en) 2007-02-23 2010-09-29 High Point Pharmaceuticals Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
JP5361857B2 (ja) 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CN101677562A (zh) * 2007-04-11 2010-03-24 高点制药有限责任公司 新化合物
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (de) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
JP5223864B2 (ja) 2007-06-27 2013-06-26 大正製薬株式会社 １１β−ＨＳＤ１阻害活性を有する化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
EP2272841A1 (de) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamidderivat mit antagonistischer wirkung auf rezeptor des melaninkonzentrierenden hormons
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5635991B2 (ja) 2008-10-30 2014-12-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． イソニコチンアミドオレキシン受容体アンタゴニスト
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
KR200452117Y1 (ko) * 2008-11-10 2011-02-08 대성공업주식회사 휠체어용 브레이크 와이어 케이블 지지 브래킷
JP2012509879A (ja) * 2008-11-21 2012-04-26 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー アダマンチルベンズアミド化合物
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CN103204824B (zh) * 2012-01-12 2015-04-08 清华大学深圳研究生院 2-氨基噻唑-4-酰胺类衍生物及其制备方法与应用
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN105001152A (zh) * 2015-07-19 2015-10-28 佛山市赛维斯医药科技有限公司 一类二甲胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途
CN105017135A (zh) * 2015-07-19 2015-11-04 佛山市赛维斯医药科技有限公司 一类二吡啶叔醇结构的11β-HSD1抑制剂、制备方法及其用途
EP3235813A1 (de) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo-derivate
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN107663204A (zh) * 2016-10-19 2018-02-06 首都医科大学附属北京世纪坛医院 一种化合物的抗结核应用
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3717459B1 (de) 2017-11-30 2026-01-21 Step Pharma S.A.S. Verbindungen
WO2019106146A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
JP7214743B2 (ja) 2018-02-15 2023-01-30 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法
CN108358869B (zh) * 2018-03-27 2019-09-10 河北师范大学 一种n-苯并噻唑基苯磺酰胺类衍生物、制备方法及用途
CN108659219B (zh) * 2018-06-08 2021-02-09 扬州大学 一种聚苯胺的制备方法
KR102919209B1 (ko) 2018-08-10 2026-01-28 다이아핀 테라퓨틱스, 엘엘씨 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
CN109748831A (zh) * 2018-12-17 2019-05-14 南通正达农化有限公司 一种三氟甲磺酸三氟乙酯的制备方法
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
WO2021030552A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
WO2021101927A1 (en) 2019-11-18 2021-05-27 Vanderbilt University Wdr5-myc inhibitors
CN111620837B (zh) * 2020-06-29 2022-02-15 郑州大学 香柏酮噻唑酰胺类化合物、及其制备方法和应用
BR112023002957A2 (pt) 2020-08-18 2023-04-04 Merck Sharp & Dohme Llc Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
US20230373974A1 (en) * 2020-10-07 2023-11-23 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN112451514A (zh) * 2020-11-26 2021-03-09 江西农业大学 二氢杨梅素纳米硒及其制备方法和应用
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
CN113461635A (zh) * 2021-07-07 2021-10-01 上海毕得医药科技股份有限公司 4-（2-氯乙基）噻唑-2-羧酸乙酯及其制备方法和应用
CN118103038A (zh) * 2021-08-20 2024-05-28 英安塔制药有限公司 17β-羟基类固醇脱氢酶13型抑制剂及其使用方法
CN117105824A (zh) * 2023-08-26 2023-11-24 衢州市九洲化工有限公司 一种三氟甲磺酸三氟乙酯的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB517272A (en) 1938-06-03 1940-01-25 May & Baker Ltd The preparation of new therapeutically useful heterocyclic compounds
GB620654A (en) * 1939-10-03 1949-03-29 Chinoin Gyogyszer Es Vegyeszet A process for the preparation of sulphonamide derivatives of 2-amino-thiazole
US2611770A (en) * 1949-04-16 1952-09-23 American Cyanamid Co N-(2-thiazolyl)-2-hydroxypyridine-5-sulfonamides
GB822947A (en) 1957-01-25 1959-11-04 Smith & Nephew Improvements in and relating to sulphonamides
DE1620508A1 (de) * 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
CA1088049A (en) 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
FR2384498A1 (fr) 1975-11-26 1978-10-20 Parcor Nouveaux derives sulfonylamino thiazoliques et leurs applications en medecine humaine et veterinaire
EP0246749A3 (de) * 1986-05-17 1988-08-31 AgrEvo UK Limited Herbizide Triazole
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH021483A (ja) 1988-03-10 1990-01-05 Nippon Tokushu Noyaku Seizo Kk 農業用殺菌剤
JPH078863B2 (ja) 1989-09-21 1995-02-01 久光製薬株式会社 新規なジフェニルチアゾール誘導体
DE69206725T2 (de) * 1991-09-10 1996-05-02 Zeneca Ltd Benzolsulfonamidderivate als 5-Lipoxygenasehemmer
JPH0670024B2 (ja) 1993-04-13 1994-09-07 塩野義製薬株式会社 グルタコン酸エステル誘導体の製法
US6030991A (en) 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
JPH07149745A (ja) * 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−アミノチアゾール誘導体
JPH07149746A (ja) * 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−置換アミノチアゾール誘導体
JPH07309757A (ja) * 1994-05-18 1995-11-28 Asahi Chem Ind Co Ltd βアミロイド蛋白神経細胞毒性低減剤
SI0779810T1 (en) 1994-08-09 2003-12-31 Cortendo Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
AU689972B2 (en) * 1994-11-29 1998-04-09 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
SE505391C2 (sv) 1995-05-30 1997-08-18 Cortendo Ab Användning av kortisol-agonister för framställning av ett system för diagnostisering av det metabola syndromet
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
GB9517622D0 (en) * 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
WO1997047299A1 (en) * 1996-06-12 1997-12-18 3-Dimensional Pharmaceuticals, Inc. Amidino and guanidino heterocyclic protease inhibitors
US5877193A (en) 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
WO1998016520A1 (en) 1996-10-16 1998-04-23 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
US5783597A (en) 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
AU736256B2 (en) 1997-07-11 2001-07-26 Smithkline Beecham Plc Novel compounds
GB9725141D0 (en) 1997-11-27 1998-01-28 Pharmacia & Upjohn Spa Benzenesulfonamide compounds
CA2332325A1 (en) 1998-06-18 1999-12-23 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
GB9915625D0 (en) 1999-07-02 1999-09-01 Cortendo Ab Method
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
IT1317735B1 (it) 2000-01-26 2003-07-15 Nicox Sa Sali di agenti antimicrobici.
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2002213048A1 (en) 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
GB0118300D0 (en) 2001-07-26 2001-09-19 Cortendo Ab Formulations
RS44304A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1
AU2002353718B2 (en) 2001-11-22 2007-05-10 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20030130279A1 (en) 2001-11-22 2003-07-10 Guido Kurz Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
RS44204A (sr) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitori 11-beta- hidroksistereoidne dehidrogenaze tipa 1

Also Published As

Publication number Publication date
ZA200209362B (en) 2004-02-18
JP2003534337A (ja) 2003-11-18
CA2408783A1 (en) 2001-11-29
JP2003534336A (ja) 2003-11-18
US20030166689A1 (en) 2003-09-04
WO2001090093A1 (en) 2001-11-29
AR033534A1 (es) 2003-12-26
KR20030011341A (ko) 2003-02-07
NO20025585D0 (no) 2002-11-21
NO20025587L (no) 2003-01-21
CN1438997A (zh) 2003-08-27
ES2333846T3 (es) 2010-03-02
NO20025585L (no) 2002-12-23
US20100113435A1 (en) 2010-05-06
CA2409697C (en) 2010-07-13
KR20030016271A (ko) 2003-02-26
WO2001090090A1 (en) 2001-11-29
WO2001090094A1 (en) 2001-11-29
US20030176476A1 (en) 2003-09-18
US20040224996A1 (en) 2004-11-11
AU6093201A (en) 2001-12-03
NO323832B1 (no) 2007-07-09
NZ522538A (en) 2004-09-24
BR0111099A (pt) 2003-04-15
NO20025586D0 (no) 2002-11-21
CN1249039C (zh) 2006-04-05
DE60143293D1 (de) 2010-12-02
HK1056878A1 (en) 2004-03-05
CA2409697A1 (en) 2001-11-29
US7132436B2 (en) 2006-11-07
AU6445601A (en) 2001-12-03
NZ522591A (en) 2004-09-24
CN1188403C (zh) 2005-02-09
CA2408144A1 (en) 2001-11-29
WO2001090091A1 (en) 2001-11-29
AU2001262831B2 (en) 2006-12-21
AU2001262831B9 (en) 2007-08-09
NO20025588D0 (no) 2002-11-21
ATE443055T1 (de) 2009-10-15
EP1283832B1 (de) 2010-10-20
ZA200209360B (en) 2004-02-18
US7125900B2 (en) 2006-10-24
EP1283832A1 (de) 2003-02-19
ZA200209359B (en) 2004-02-18
HUP0302435A3 (en) 2007-05-02
CA2408144C (en) 2009-11-24
HUP0302435A2 (hu) 2003-12-29
IL152669A0 (en) 2003-06-24
NO323779B1 (no) 2007-07-02
NO20025586L (no) 2003-01-21
EA005274B1 (ru) 2004-12-30
US7030135B2 (en) 2006-04-18
NO323831B1 (no) 2007-07-09
AU6093101A (en) 2001-12-03
NO20025588L (no) 2002-12-20
NZ522507A (en) 2004-11-26
US20060160797A1 (en) 2006-07-20
NZ522506A (en) 2004-08-27
IL152753A0 (en) 2003-06-24
NO20025587D0 (no) 2002-11-21
US7618961B2 (en) 2009-11-17
DE1283831T1 (de) 2003-08-14
PE20020100A1 (es) 2002-02-13
CN1430614A (zh) 2003-07-16
KR20030016269A (ko) 2003-02-26
US20060287374A1 (en) 2006-12-21
IL152790A0 (en) 2003-06-24
JP2003534338A (ja) 2003-11-18
AU2001262830A1 (en) 2001-12-03
US20030199501A1 (en) 2003-10-23
MXPA02011632A (es) 2004-05-05
EP1283833A1 (de) 2003-02-19
ZA200209364B (en) 2004-02-18
EA200201271A1 (ru) 2003-04-24
KR20030016272A (ko) 2003-02-26
PL360137A1 (en) 2004-09-06
CN1430615A (zh) 2003-07-16
IL152670A0 (en) 2003-06-24
WO2001090092A1 (en) 2001-11-29
EP1283834B1 (de) 2009-09-16
CN1437588A (zh) 2003-08-20
EP1283831A1 (de) 2003-02-19
JP2003534339A (ja) 2003-11-18
CA2408142C (en) 2009-10-20
SE0001899D0 (sv) 2000-05-22
WO2001090091A8 (en) 2002-07-25
CA2408142A1 (en) 2001-11-29
DE60139931D1 (de) 2009-10-29
EP1283834A1 (de) 2003-02-19
AU6283101A (en) 2001-12-03

Similar Documents

Publication Publication Date Title
ATE485283T1 (de) Inhibitoren der 11-beta-hydroxy-steroid- dehydrogenase des typs 1
ATE524441T1 (de) Vla-4-inhibitoren
IS2932B (is) Fúlvestrant samsetning
IS6762A (is) Spíró-pýrimídín-2,4,6-tríón málmpróteinasa hindrar
DK1265511T3 (da) Tandbørste
PT1250047E (pt) Composicao herbicida
ATE303787T1 (de) Schergelzusammensetzungen
AR028197A1 (es) Composiciones antitranspirantes
NO20030591D0 (no) Overflateaktiv forbindelse
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
DE60112774D1 (de) Reibungsarme zahnbürste
NO20030589L (no) Overflateaktiv forbindelse
DE60116858D1 (de) Zusammensetzung
DE10196172T1 (de) Mehrpoliger Pinsel
NO20030868L (no) N-(3,5-diklor-2-metoksyfenyl)-4-metoksy-3-piperazin-1-yl- benzensulfonamid
DE50113112D1 (de) Schaltungsanordnung
AR028075A1 (es) Inhibidores de la peptido-desformilasa
DE60107312D1 (de) Feste Zusammensetzung
DE60114796D1 (de) Analgetisch wirksame benzosuberonylpiperidin-verbindungen
EP1354589A4 (de) Angiogenese-hemmer
DE50115426D1 (de) Schaltungsanordnung
ATA11302000A (de) Beizanlage
ITPS20000011A1 (it) Hout 1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties